Ovarian Cancer
Conditions
Keywords
Epithelial ovarian cancer, BRCA mutation, Platinum resistant, Platinum sensitive, Relapsed ovarian cancer
Brief summary
The purpose of this study is to investigate the effect of combined topotecan and veliparib (ABT888) treatment in relapsed ovarian cancer with tumor progression and negative or unknown BRCA mutation status.
Interventions
DRUGVeliparib
Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
DRUGTopotecan
2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
Sponsors
Abbott
Vejle Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed epithelial, primary fallopian or primary peritoneal cancer. 2. Verified progression by either RECIST criteria and/or GCIG CA125 criteria after previous first line chemotherapy or progression after later lines of cytotoxic treatment. 3. Platinum resistance or partially platinum sensitive disease * Relapsed within six months of prior first line/later lines of platinum-based therapy or * Relapsed within six-twelve months of prior first line/later lines of platinum-based therapy 4. Age ≥ 18 years. 5. Performance status 0-2. 6. Measurable disease by RECIST 1.1 or CA125 GCIG criteria 7. Adequate bone marrow function, liver function, renal function and coagulation parameters (within 7 days prior to enrollment): * WBC ≥ 3.0 x 10\^9/l or neutrophils (ANC) ≥ 1.5 x 10\^9/l * Platelet count ≥ 100 x 109/l * Hemoglobin ≥ 9.7 g/dl (6 mmol/L) * Serum bilirubin ≤ 1.5 x ULN * Serum transaminases ≤ 2.5 x ULN * Serum creatinine ≤ 1.5 x ULN 8. Written informed consent. 9. Tissue available for BRCAness analysis/BRCA mutation analysis.
Exclusion criteria
1. Prior treatment with a PARP inhibitor. 2. Patients with BRCA1/2 germline mutation. 3. Platinum-refractory disease (disease that progressed or was stable during prior platinum therapy) 4. Patients who have received (or are planning to receive) treatment with any other investigational agent, or who have participated in another clinical trial within 28 days prior to entering this trial. 5. Pregnant or breast-feeding. For fertile women a negative pregnancy test at screening is mandatory. 6. Fertile patients not willing to use acceptable and safe methods of contraception during and for 6 months after treatment 7. Other present or previous malignancy except curatively treated cervical cancer stage I, non-melanotic skin cancer or other cancer with minimal risk of relapse. Previous breast cancer is allowed, if disease free follow-up at least five years prior to enrollment. 8. CNS metastasis. 9. History of any chronic medical or psychiatric condition or laboratory abnormality, which is not medically controlled or in the opinion of the Investigator may increase the risks associated with study drug administration (e.g. diabetes, cardiac diseases, hypertension, renal or liver disease). 10. Allergy to the ingredients of the study medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase I: Maximum tolerated dose, dose limiting toxicity and thus recommend phase II dose of veliparib | 1 month |
| Phase II: To investigate response rates (based on either CA125 GCIG or RECIST criteria) of combination topotecan and veliparib (ABT888) in relapsed ovarian cancer with negative or unknown BRCA status | Every three months, up to 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival of ovarian cancer patients treated with topotecan and veliparib | Every three months up to three years |
| Overall survival of ovarian cancer patients treated with topotecan and veliparib | Every three months, up to three years |
Countries
Denmark
Outcome results
None listed